Clinical Trial Update: GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial of vismodegib (GDC-0449) in patients with recurrent glioblastoma multiforme that could be surgically removed; the study is complete and results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Vismodegib (Vismodegib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2017-08-16